A role for plasmin in platelet aggregation: Differential regulation of IGF release from IGF-IGFBP complexes?

Growth Hormone and IGF Research

Volumn 18, Issue 4, 2008, Pages 325-334

  Marcinkiewicz, Marek ^a   Gordon, Phillip V ^a  

^a UNIVERSITY OF VIRGINIA CHILDREN S HOSPITAL   (United States)

Author keywords

Aggregation; IGF binding protein; Insulin like growth factor; Plasmin; Platelet aggregation

Indexed keywords

ADENOSINE DIPHOSPHATE; LIGAND; PLASMIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ARTICLE; CELL ASSAY; CONTROLLED STUDY; ENZYME ACTIVITY; HORMONE ACTION; HORMONE RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DETERMINATION; REGULATORY MECHANISM; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

BLOOD PLATELETS; HUMANS; INDOMETHACIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MODELS, BIOLOGICAL; MULTIPROTEIN COMPLEXES; PLASMIN; PLATELET AGGREGATION; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; SOMATOMEDINS;

EID: 44349174285     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2008.01.004     Document Type: Article

References (31)

1. Wilgus T.A. Regenerative healing in fetal skin: a review of the literature. Ostomy Wound Manage. 53 (2007) 16-31
2. Park J.H., McCusker R.H., Vanderhoof J.A., Mohammadpour H., Harty R.F., and MacDonald R.G. Secretion of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 by intestinal epithelial (IEC-6) cells: implications for autocrine growth regulation. Endocrinology 131 (1992) 1359-1368
3. Kahner B.N., Shankar H., Murugappan S., Prasad G.L., and Kunapuli S.P. Nucleotide receptor signaling in platelets. J. Thromb. Haemost. 4 (2006) 2317-2326
4. Gachet C., and Cazenave J.P. ADP induced blood platelet activation: a review. Nouv. Rev. Fr. Hematol. 33 (1991) 347-358
5. Motani A.S., Anggard E.E., and Ferns G.A. Recombinant insulin-like growth factor-1 modulates aggregation in human platelets via extracellular calcium. Life Sci. 58 (1996) 269-274
6. Ervin A.L., and Peerschke E.I. Platelet activation by sustained exposure to low-dose plasmin. Blood Coagul. Fibrinolysis. 12 (2001) 415-425
7. Kawano K., Aoki I., Aoki N., et al. Human platelet activation by thrombolytic agents: effects of tissue-type plasminogen activator and urokinase on platelet surface P-selectin expression. Am. Heart J. 135 (1998) 268-271
8. Frost V.J., Macaulay V.M., Wass J.A., and Holly J.M. Proteolytic modification of insulin-like growth factor-binding proteins: comparison of conditioned media from human cell lines, circulating proteases and characterized enzymes. J. Endocrinol. 138 (1993) 545-554
9. Booth B.A., Boes M., Dake B.L., and Bar R.S. Isolation and characterization of plasmin-generated bioactive fragments of IGFBP-3. Am. J. Physiol. 276 (1999) E450-E454
10. Denley A., Cosgrove L.J., Booker G.W., Wallace J.C., and Forbes B.E. Molecular interactions of the IGF system. Cytokine Growth Factor Rev. 16 (2005) 421-439
11. Russo V.C., Gluckman P.D., Feldman E.L., and Werther G.A. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr. Rev. 26 (2005) 916-943
12. Skjaerbaek C., Frystyk J., Orskov H., et al. Differential changes in free and total insulin-like growth factor I after major, elective abdominal surgery: the possible role of insulin-like growth factor-binding protein-3 proteolysis. J. Clin. Endocrinol. Metab. 83 (1998) 2445-2449
13. Blat C., Villaudy J., and Binoux M. In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. J. Clin. Invest. 93 (1994) 2286-2290
14. Desreumaux P., Huet G., Zerimech F., et al. Acute inflammatory intestinal vascular lesions and in situ abnormalities of the plasminogen activation system in Crohn's disease. Eur. J. Gastroenterol. Hepatol. 11 (1999) 1113-1119
15. Wilczak N., Elting J.W., Chesik D., Kema I.P., and De Keyser J. Intravenous tissue plasminogen activator in patients with stroke increases the bioavailability of insulin-like growth factor-1. Stroke 37 (2006) 2368-2371
16. Taylor V.L., and Spencer E.M. Characterisation of insulin-like growth factor-binding protein-3 binding to a novel receptor on human platelet membranes. J. Endocrinol. 168 (2001) 307-315
17. Street M.E., Seghini P., Ziveri M.A., Fieni S., Volta C., Neri T.M., Viani I., Bacchi-Modena A., and Bernasconi S. Interleukin-6 and insulin-like growth factor system relationships and differences in the human placenta and fetus from the 35th week of gestation. Growth Horm. IGF Res. 16 (2006) 365-372
18. Gordon P.V., Paxton J.B., Kuemmerle J.F., and Fox N.S. Related articles, links A 14-kDa cathepsin l-derived carboxyl IGFBP-2 fragment is sequestered by cultured rat ileal crypt cells. Am. J. Physiol. Gastrointest. Liver Physiol. 289 (2005) G79-G87
19. Gear A.R. Rapid reactions of platelets studied by a quenched-flow approach: aggregation kinetics. J. Lab. Clin. Med. 100 (1982) 866-886
20. Gear A.R. Preaggregation reactions of platelets. Blood 58 (1981) 477-490
21. Maurer-Spurej E., Pfeiler G., Maurer N., Lindner H., Glatter O., and Devine D.V. Room temperature activates human blood platelets. Lab. Invest. 81 (2001) 581-592
22. Spencer E.M., Tokunaga A., and Hunt T.K. Insulin-like growth factor binding protein-3 is present in the alpha-granules of platelets. Endocrinology 132 (1993) 996-1001
23. Oh Y., Muller H.L., Lee D.Y., Fielder P.J., and Rosenfeld R.G. Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1-4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs. Endocrinology 132 (1993) 1337-1344
24. Denley A., Brierley G.V., Carroll J.M., Lindenberg A., Booker G.W., Cosgrove L.J., Wallace J.C., Forbes B.E., and Roberts Jr. C.T. Differential activation of insulin receptor isoforms by insulin-like growth factors is determined by the C domain. Endocrinology 147 (2006) 1029-1036
25. Falcon C., Pfliegler G., Deckmyn H., and Vermylen J. The platelet insulin receptor: detection, partial characterization, and search for a function. Biochem. Biophys. Res. Commun. 157 (1988) 1190-1196
26. Schini V.B., Catovsky S., Schray-Utz B., Busse R., and Vanhoutte P.M. Insulin-like growth factor I inhibits induction of nitric oxide synthase in vascular smooth muscle cells. Circ. Res. 74 (1994) 24-32
27. Kim S., Garcia A., Jackson S.P., and Kunapuli S.P. Insulin-like growth factor-1 regulates platelet activation through PI 3-K{alpha} isoform. Blood (2007) (September) (E-pub ahead of print)
28. Hers I. Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3K{alpha} pathway. Blood (2007) (September) (Epub ahead of print)
29. Borsch-Haubold A.G., Bartoli F., Asselin J., et al. Identification of the phosphorylation sites of cytosolic phospholipase A2 in agonist-stimulated human platelets and HeLa cells. J. Biol. Chem. 273 (1998) 4449-4458
30. Haq S., Kilter H., Michael A., et al. Deletion of cytosolic phospholipase A2 promotes striated muscle growth. Nat. Med. 9 (2003) 944-951
31. Kol S., Ben-Shlomo I., Ando M., and Adashi E.Y. Insulin-like growth factor I affects the intraovarian interleukin-1 system: evidence for suppression of type I interleukin-1 receptor expression and enhancement of secretory phospholipase A2 expression and activity. Mol. Hum. Reprod. 3 (1997) 1095-1099